FACULTY DISCLOSURES
As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity.
The faculty of this CME activity disclose the following:
Dr Del Rosso has received grant/research support from, is a consultant to, and is on the speaker’s bureau of Abbott, Amgen Inc., Astellas Pharma Inc., CollaGenex Pharmaceuticals Inc., Coria Laboratories Ltd., Galderma Laboratories, L.P., Intendis, Medicis Pharmaceutical Corporation, OrthoNeutrogena, QLT Inc., Ranbaxy Laboratories Limited, Stiefel Laboratories, Inc., and Warner Chilcott.
Dr Harper is a consultant to Intendis and a speaker’s bureau of Allergan, Inc., Stiefel Laboratories, Inc., and CollaGenex Pharmaceuticals Inc.
Dr Tanghetti is a consultant to Stiefel Laboratories Inc.
Resolution of Conflict of Interest (COI)
The Elsevier Office of CME has implemented a process to resolve COI for each CME activity. In order to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public, the EOCME has resolved the conflict by external review.
Unapproved/Off-Label Use Disclosure
The EOCME requires CME faculty to disclose to the participants:
1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
